Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Raptor Pharmaceutical's Trial Failed, But Huntington's Disease Update Could Bring Gains At Year End
Yahoo/Benzinga
Tue, 09/15/15 - 11:40 am
Raptor Pharmaceutical
RP103
NASH
Huntington's disease
Raptor Pharma says may discontinue development of liver drug
Yahoo/Reuters
Mon, 09/14/15 - 08:23 am
Raptor Pharmaceutical
RP103
NASH
non-alcoholic fatty liver disease
Conatus: Emricasan's 4 Indications Present A Lucrative Opportunity In The Liver Disease Market
Seeking Alpha
Sat, 07/18/15 - 10:48 am
Conatus Pharmaceuticals
emricasan
liver disease
NASH
cirrhosis
Will This Drug Beat Gilead to Market in NASH?
Investopedia
Sat, 05/23/15 - 11:35 am
Gilead Sciences
NASH
OCA
Intercept Pharma
Boehringer snaps up Pharmaxis liver disease drug
Pharma Times
Mon, 05/18/15 - 09:06 am
Boehringer Ingelheim
Pharmaxis
NASH
PXS4728A
La Jolla dumps its NASH drug and shifts its focus to rare disease
Fierce Biotech
Fri, 05/8/15 - 09:05 am
La Jolla Pharmaceutical
NASH
GCS-100
LJPC-1010
Tobira pulls off a $40M Wall Street end-around with sights set on NASH
Fierce Biotech
Tue, 05/5/15 - 09:41 am
Tobira Pharmaceuticals
NASH
Regado Biosciences
Genfit to conduct large liver drug trial despite setback
Yahoo/Reuters
Thu, 03/26/15 - 09:27 pm
Genfit
NASH
GFT-505
4 Biotech Reports This Month That Could Move Stocks
Investors.com
Thu, 03/19/15 - 08:15 am
Biogen Idec
BIIB037
Genfit
NASH
GFT-505
Vertex Pharmaceuticals
VX-661
Merck
grazoprevir
New market for liver disease spawns race for better testing
Yahoo/Reuters
Wed, 03/18/15 - 08:20 am
liver disease
NASH
diagnostics
Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know.
TheStreet.com
Thu, 03/12/15 - 07:53 am
Genfit
NASH
GFT505
Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD
Yahoo
Thu, 03/5/15 - 08:49 am
patents
Islet Sciences
SGLT2 inhibitor
NASH
NAFLD
Genfit is next up in the M&A rumor mill thanks to its NASH drug
Fierce Biotech
Wed, 03/4/15 - 10:12 am
Genfit
M&A
NASH
GFT505
Gilead Sciences to liver disease treatment from Phenex for as much as $470 million
Yahoo/AP
Tue, 01/6/15 - 03:36 pm
Gilead Sciences
Phenex
NASH
liver disease
IPO Stock Watch: FibroGen Up With Liver-Disease Field
Investors.com
Tue, 01/6/15 - 08:41 am
IPOs
FibroGen
liver disease
NASH
Arena's Smoking Cessation, Nash, Combination Belviq-Phentermine and Free Belviq Samples
Seeking Alpha
Mon, 11/24/14 - 11:39 am
Arena Pharmaceuticals
smoking cessation
NASH
Belviq-Phentermine
samples
Biotech stocks to watch ahead of liver disease conference
CNBC
Fri, 11/7/14 - 03:54 pm
liver disease
Gilead Sciences
Intercept Pharma
Genfit
Merck
Achillion
AbbVie
NASH
hepatitis B
hepatitis C
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
Yahoo/AccessWire
Thu, 07/24/14 - 11:39 am
Galectin
Intercept Pharmaceuticals
NASH
The next hepatitis C? NASH
CNBC
Tue, 07/15/14 - 09:48 am
NASH
hepatitis C
liver disease
nonalcoholic steatohepatitis
Genfit
Gilead Sciences
Intercept Pharma
Liver Drug Race: Intercept Pharma Vs. Rivals
Seeking Alpha
Mon, 01/27/14 - 08:21 am
Intercept Pharma
liver disease
OCA
Conatus Pharmaceuticals
Gilead Sciences
Galectin
NASH
non-alcoholic fatty liver disease
Pages
« first
‹ previous
…
7
8
9
10
11
12
13
14
15